On The Trail of Disease in Southeast Asia by Maxmen, Amy
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In 2000, an international team of doctors 
affiliated with the University of Oxford 
congregated in Laos to help tackle a dev-
astating problem. Trembling, feverish 
villagers were being treated for malaria, 
whether they had the disease or not. 
With no accessible blood culture service, 
it was nearly impossible to determine the 
cause of fevers and other malaria-like 
symptoms. In the following years, the 
visiting doctors worked with Lao doc-
tors to implement routine blood cultures 
for patients hospitalized with fevers. 
Malaria turned out to be relatively rare. 
Instead, many suffered from typhoid, 
Staphylococcus, and Escherichia coli infec-
tions (1). Just three days of antibiotics 
would have saved so many lives, reflects 
Nick Day, an infectious disease researcher 
in Thailand.
I take the train across Bangkok to 
meet Day, where he directs a collabora-
tive center for disease research called 
MORU (Mahidol-Oxford Tropical 
Medicine Research Unit). By the time 
I reach downtown, torrential rain dark-
ens the sky but does nothing to cool the 
air or slow the crowds that flow be-
tween animated vendors of mangoes, 
durians, donuts, fried chicken, and 
cheap socks. At 6 feet tall, Day sticks 
out above the masses. Raising a pink 
and white Hello Kitty umbrella, he 
shouts over the droning downpour and 
human murmurs, inviting me to tour 
their new laboratories.
As we dodge puddles in the eroded 
pavement, I ask Day if he thinks rural 
areas are prepared to handle emerging out-
breaks of virulent pathogens. He pauses 
and says in a hybrid drawl—part Ox-
bridge, part Ugandan—“First, we don’t 
even know what’s out there.” In poor 
rural regions, he says, “we still don’t 
know what is actually responsible for 
morbidity and mortality.”
Since Day’s arrival six years ago, 
funding from outside institutions has in-
creased with the acknowledgment that 
epidemics arising in Asia won’t stay put. 
People travel and goods are shipped. 
Microbes move. A Nature study last Jan-
uary analyzed 335 infectious disease out-
breaks between 1940 and 2004 and 
concluded that infectious diseases are, 
indeed, on the rise (2). Bacteria ac-
counted for more than half of the emerg-
ing infectious diseases in the study, and 
many of these were drug resistant. Pov-
erty, population density, and changing 
agricultural practices conspire to make 
Southeast Asia a hot spot for outbreaks, 
according to the lead author on the 
study, parasitologist Peter Daszak.
Half of the world’s population lives in 
Asia, often in close quarters with pathogen-
carrying animals like chickens and pigs. 
In impoverished regions of Cambodia, 
Myanmar, Indonesia, Laos, Vietnam, and 
Thailand, microbiology laboratories are 
rare and diseases go undiagnosed. And 
misuse of antimicrobials generates newer, 
stronger strains. The consequences of 
neglect  are dire. People die needlessly. 
Outbreaks gain momentum.
“I’ve begun to worship good diag-
nostics,” laughs Sarah Dunstan, an 
Australian researcher at the Oxford 
University Clinical Research Unit 
in Ho Chi Minh City, Vietnam, 
who was in Bangkok for a recent 
Keystone symposium on emerg-
ing infectious diseases. The im-
mensity of what is unknown 
about the pathogens underlying 
human mortality allows the epi-
demiologists of Southeast Asia to 
churn out data in the form of sur-
veys and drug efficacy trials. “But 
these aren’t sexy studies,” Dunstan 
sighs, acknowledging disinterest 
The microbes found in the first routine blood cultures 
taken at a hospital in Vientiane, Laos, 2000-2004.
Infectious disease research is blossoming in cities like 
Bangkok, as local clinicians and scientists delve into the 
surrounding muddy tropics of Southeast Asia to learn 
about endemic pathogens.
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among many scientists and grant-making 
agencies in the industrialized world who 
often prefer fundamental research. In-
stead of, say, hypothesis-driven forays 
into T cell responses in mouse models of 
human disease, many researchers in 
Southeast Asia conduct fever studies. 
They ask why people die. It’s highly rel-
evant, but low in glory.
Although securing funds remains a 
challenge, new initiatives for disease sur-
veillance and medical infrastructure offer 
hope. This past November, for example, 
the Bill and Melinda Gates Foundation do-
nated more than $22 million to the World 
Health Organization (WHO) for the con-
trol and monitoring of drug-resistant ma-
laria in Southeast Asia. In 2007, the UK’s 
Wellcome Trust put approximately $19 
million into disease research in Southeast 
Asia, much of it going to University of 
Oxford–affiliated institutions like MORU.
The effects of donations are beginning 
to show. Day beams as we cross the gleam-
ing linoleum of MORU’s laboratory 
floors. MORU’s building in Bangkok has 
quadrupled in size since renovations began 
in 2002. Founded in 1979 as a collabora-
tion between the University of Oxford and 
Mahidol University in Bangkok, MORU 
now forms a hub for ongoing studies in af-
filiated centers and hospitals around Thai-
land, Laos, Vietnam, Cambodia, Bangladesh, 
India, and Myanmar. The Wellcome Trust 
also recently granted Day’s hopeful gradu-
ate student, Emma Nickerson, the funding 
she had been persistently begging for.
CHARTING TERRA INCOGNITA
Over beer and curry at a teakwood house 
with a towering gate and a sweeping gar-
den, set back from the noise and exhaust 
of nearby Sukhumvit Road, Nickerson 
smiles. She mentions that she hadn’t set 
foot in Southeast Asia before deciding to 
leave the comforts of the British hospital 
where she completed her medical resi-
dency. Since 2003, she’s spent most of 
every year in Ubon Ratchathani, a prov-
ince in northeastern Thailand bordered 
by Laos to the east and Cambodia to the 
south. There, farmers who till rice pad-
dies commonly fall ill with meloidosis, a 
life-threatening infection caused by Buk-
holderia pseudomallei. Oddly enough, peo-
ple also appeared to be dying from 
Staphylococcus aureus, a bacterium known 
to plague American hospitals but not 
generally considered problematic in the 
developing world. Nickerson’s work is 
beginning to change that misperception.
“I’m still trying to dispel the myth 
that staph isn’t a tropical disease,” Nick-
erson remarks. In a letter published in 
Lancet in 2006, she reported that 9% of 
bloodstream bacterial infections at Sappa-
sithiprasong Hospital in Ubon Ratchathani 
province are caused by S. aureus (3). An-
other recent survey in Laos found that 
S. aureus was the leading cause of bacte-
rial infection in infants less than one year 
of age (1).
But many epidemiological trends like 
this one continue to go unnoticed in re-
gions of the developing world where mi-
crobiology laboratories are in short supply 
and clinics struggle to handle emergency 
situations, never mind conduct long-term 
studies. To reach scattered hospitals, the 
ill must travel miles by foot, canoe, mule, 
truck, and inconsistent train. They come 
sweating and shivering with malaria, suf-
focating from tuberculosis, or dizzy from 
the pain of swollen abscesses. Full hospi-
tals rarely turn them away. “There are 
only 1,000 beds at Sappasithiprasong 
Hospital,” Nickerson says, “but they 
always make space.”
Nickerson conducted the first study 
tracking disease progression in patients 
infected with S. aureus in Thailand in 
2003. Before her arrival, overextended 
hospital staff members were unable to 
follow up with patients to check if their 
infections cleared after they were dis-
charged from the hospital. By collaborat-
ing with Thai clinicians, Nickerson 
learned the local lingo. To work out 
when bacteria most likely entered a pa-
tient’s bloodstream, she no longer asks 
for exact dates. Instead she searchers for 
landmarks; holidays or rice farming 
events that trigger memories about 
when the first fever hit.
S. aureus strains also vary considerably 
over homogenous terrain, says Nickerson. 
Siem Reap, Cambodia, is just 140 km 
south of Ubon Ratchathani, and though 
similar palms and rice paddies dominate 
the landscape, the microfauna varies. S. 
aureus strains acquired there can be reli-
ably killed with oral antibiotics, whereas 
strains from northern Thailand are often 
drug resistant. At Sappasithiprasong Hos-
pital, Nickerson found that 23–27% of 
staph infections were a potentially lethal 
variety of drug-resistant S. aureus (3).
Nickerson continues to profile strains 
from hospitals across 10 Asian countries. 
This is important information to have be-
cause delays in proper treatment lower 
the chance of survival. “People think you 
can just take data from wealthy countries 
and assume it’s true for all countries,” she 
says. “Asia is a patchwork; that’s particu-
larly relevant in terms of resistance. 
There’s so little data, actually. We’ve 
hardly scratched the surface.”
CONSEQUENCES OF NEGLECT
The emerging infections of highest prior-
ity are drug-resistant strains of well-known 
diseases like tuberculosis and malaria. Re-
sistance has been fueled in part by unregu-
lated sales of real and counterfeit medicine. 
Overuse of over-the-counter antibiotics 
speeds up bacterial evolution by selecting 
for strains that have acquired resistance. 
And counterfeits, which contain just 
enough medicine to foil screening tests, 
kill off only the most sensitive microbes.
To investigate the extent of the coun-
terfeit problem, a local researcher dressed 
as a Burmese migrant worker visited 
shops in 16 villages around the Thai–
Nick Day directs a center for tropical disease 
research in Bangkok.
“Just three days of antibiotics would 
have saved so many lives.” 
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Myanmar border in 2000. He purchased 
50 packets of “yaa chud,” a medicine 
widely taken to battle malaria around ru-
ral parts of Southeast Asia. In the seven 
packets that actually contained effective 
malaria medicine, the active ingredient 
was at low levels (4).
Recent studies estimate that 38–52% 
of the drugs supposedly containing arte-
sunate—the cornerstone drug against the 
deadliest of malaria parasites, Plasmodium 
falciparum—are counterfeit. “We make 
no apology for the use of the term man-
slaughter to describe this criminal lethal 
trade,” said researchers in a 2006 PLoS 
Medicine report (5).
In October 2008, cases of artesu-
nate-resistant malaria caused by P. fal-
ciparum  were noted along the 
Thai–Cambodia border—a volatile 
area that had already proven ripe for 
the development of resistance to other 
antimalarial drugs. P. falciparum attacks 
not only the blood and liver but also 
the brain, often leading to seizures, or-
gan failure, and death. It accounts for 
most of the approximately one million 
malaria-related deaths each year, ac-
cording to the WHO. In Southeast 
Asia, approximately 90–160 million 
people are infected with malaria each 
year, and 120,000 die.
Borderland health care is notoriously 
poor. Most doctors in the area request 
transfers because of political unrest. And 
the counterfeit drug industry thrives. An 
estimated 918,000 migrants, including 
refugees in camps, dwell or pass through 
the Thai–Cambodia border each year, 
possibly carrying resistant bugs with them. 
In the early 1970s, the region spawned P. 
falciparum strains resistant to the antimalar-
ial drug chloroquine. Resistance spread like 
wildfire. Now the drug is almost totally 
ineffective in Southeast Asia, Africa, and 
most other parts of the world. Resistance 
to replacement drugs—first sulfadoxine-
pyrimethamine, and then mefloquine—
occurred in the region a few years after 
they replaced chloroquine.
With no alternative treatments for se-
vere malaria caused by P. falciparum, the 
consequences of widespread artesunate 
resistance would be disastrous, says Day. 
Six UN agencies, including the WHO, 
and more than a dozen international 
nongovernmental organizations currently 
work along the border to improve health 
care. Groups at Mahidol University and 
the Armed Forces Research Institute of 
Medical Sciences (AFRIMS) in Bang-
kok, the Cambodian National Malaria 
Control Program, the Sanger Institute in 
the UK, the Southwest Foundation for 
Biomedical Research in San Antonio, 
Texas, and Nanyang Technological Uni-
versity in Singapore are furiously studying 
artesunate profiles, parasite transcrip-
tomes, and patient microarrays. “This is 
very collaborative since we’ve got to nail 
it,” Day says. “We can’t worry about 
who’s first author on the paper.”
LOCALS RESPOND
Photographs of human suffering lined the 
walls of the conference hall in Bangkok 
where the Keystone symposium on 
emerging infectious diseases took place 
between October 22 and 27. Scientists 
from around the world milled about be-
side the morose exhibit, sipping tea and 
nibbling mini-muffins. Those working in 
developing countries do not need the hu-
manitarian reminder. They have seen the 
frightened faces of patients dying from 
diseases that are rarely seen, or are quickly 
cured, in industrialized nations. During 
the poster session, Vasanthi Ramachan-
dran from AstraZeneca India in Bangalore 
and Ladaporn Bodhidatta from AFRIMS 
A hospital ward in Chittagong, Bangladesh.
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in Bangkok heatedly discuss the bacte-
rium  Shigellosis sonnei and the different 
ways that children from their respective 
countries respond to infection and to the 
drug treatments for the accompanying di-
arrhea, fever, and stomach cramps.
“Everything we do goes back to the 
people,” explains Jane Cardosa from the 
University of Malaysia in Sarawak. First of 
all, people need to be informed about how 
an outbreak spreads. “At the end of the 
day, we can’t rely on outside help,” Car-
dosa says. “The bird flu taught us that we 
need to build capacity locally so that we 
can respond quickly.”
Global health rests on the shoulders 
of people who work where outbreaks 
first occur—clinicians, academics, and 
people like Yongyuth Yuthavong, who 
do a little of both and also help create 
infrastructure for medical research on a 
local level. “Are we only the hands and 
feet?” he asks. “Why not the brain?”
Yuthavong was the first president of 
Thailand’s National Science and Technol-
ogy Development Agency and, between 
2006 and 2008, the country’s Minister of 
Science and Technology. He is the type of 
man who mentions these positions as ca-
sually as someone might say they used to 
work the fryer at McDonald’s.
When I see him at the Keystone sym-
posium and ask when we might schedule 
a time to talk, he warmly replies, “Let’s 
find a quiet place now.”
TRANSFORMING MEDICAL 
RESEARCH IN THAILAND
Science was not a career one could sur-
vive on when Yuthavong first began re-
search in the mid-1960s. Professors held 
other jobs during the day or in the eve-
ning. Yuthavong’s first grant, for the 
equivalent of $200, was handed to him in 
banknotes. “Do you know the word, 
‘moonlight’?” he asks.
Like many bright young Thais, 
Yuthavong completed college in London. 
“When I got back,” he says, “all my col-
leagues had left to dig gold in the US.” In 
the 1970s, to counteract a shortage of doc-
tors, the Thai government instituted a rule 
that continues today: Citizens who receive 
government scholarships must return home 
to work for twice as long as they studied 
abroad. Simultaneously, nonprofit organi-
zations like the Rockefeller Foundation 
started supplementing the income of local 
researchers in underdeveloped nations. 
Yuthavong credits the Foundation with 
helping to establish modern medical educa-
tion in Thailand. Moonlighting scientists, 
for the most part, became obsolete.
By the end of the 1970s, a number of 
outside organizations had set up institu-
tions using local researchers and clini-
cians. AFRIMS, a collaboration of the 
US Army and the Royal Thai Army, was 
established in Bangkok in 1977 to inves-
tigate infectious diseases like scrub ty-
phoid that have plagued troops for 
centuries. Soon after, the Wellcome 
Trust funded MORU. These institutions 
now employ mainly Thai researchers. In 
1983, the Thai government financed a 
research institute and funding agency 
named BIOTEC, which is now the third 
largest of Thailand’s 15 disease laborato-
ries. There, Yuthavong’s group focuses 
on the molecular biology of malaria.
Over the last three decades, commit-
ments from the private sector have enabled 
the government to make the marginal in-
vestments required to establish scientific 
research. Still, government investments for 
research and education do not reflect eco-
nomic gains by the country, says Yuthavong. 
Only 0.26% of gross domestic product in 
Thailand was spent on science in 2007, 
and less than half of that went to medical 
research. Most countries in Western Eu-
rope, the United States, and Japan spent 10 
times that amount on research and devel-
opment, between 2.5 and 3%.
The fruits of economic development 
have also not reached all regions of the 
country equally. While less than 2% of 
people living in Bangkok were below 
the poverty line in 2006, as many as 23% 
were living in poverty in surrounding 
regions, according to the WHO. In par-
ticular, the southern provinces near the 
Thai–Cambodia border remain vulner-
able to the unrecognized disease out-
breaks characteristic of poorer nations.
As news of the plummeting US 
economy sweeps headlines in Bangkok, 
many fear that the depression will infect 
Southeast Asia. If the Thai economy 
suffers, Yuthavong worries that the gov-
ernment will cut funding for science. It 
would be a setback for the work he has 
done to encourage Thai students to stay 
in research rather than pursue more lu-
crative fields. He sighs, “People cut 
from knowledge first, they cut funding 
for education and research.”
Meanwhile, back at MORU, the rain 
outside of Day’s laboratory subsides. Day 
glances toward the window at the fading 
late afternoon light and says he ought to 
go polish off a grant. A train passes through 
the view on elevated tracks, cutting be-
tween concrete buildings and passing out 
of sight. The railway stretches for miles 
beyond the city, through interminable 
rice paddies, remote villages, overgrown 
jungles, swamps. Here, an epidemiologist 
can be engrossed for a lifetime.
1. Phetsouvanh, R., et al. 2006. Am. J. Trop. 
Med. Hyg. 75:978–985.
2. Jones, K.E., et al. 2008. Nature. 
451:990–994.
3. Nickerson, E. 2006. Lancet. 6:70–71.
4. Newton, P.  2008. Am. J. Trop. Med. Hyg. 
79:662–669.
5. Newton, P.  2006. PLoS Med. 3:e32–43.
Percent of malaria cases caused by P. falciparum.
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"We need to build capacity locally so 
that we can respond quickly."
-Jane Cardosa